Ventyx Biosciences, Inc.

VTYX

US92332V1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
2.18 ^USD	-1.80%		-5.63%	-11.74%

07-01	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Small Cap Comp Value Index	CI
07-01	Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000 Value Index	CI

Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Microcap Value Index

July 30, 2024

Latest news about Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Small Cap Comp Value Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000 Value Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000E Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 2500 Value Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Microcap Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2500 Growth Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000 Growth Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 2000 Value Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2000 Growth Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell Microcap Value Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) added to Russell 3000E Value Index	06-30	CI
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 3000E Growth Index	06-30	CI
Transcript : Ventyx Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	06-11
Oppenheimer Adjusts Ventyx Biosciences Price Target to $10 From $12, Maintains Outperform Rating	06-06	MT
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results	06-05	MT
Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers	06-05	CI
Transcript : Ventyx Biosciences, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 12:00 PM	05-23
Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise	05-16	MT
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer	05-16	CI
Transcript : Ventyx Biosciences, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Ventyx Biosciences, Inc. Announces Resignation of Christopher Krueger as Chief Business Officer, Effective on April 15, 2024	04-05	CI
Transcript : Ventyx Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM	03-14
Canaccord Genuity Trims Price Target on Ventyx Biosciences to $15 From $16, Maintains Buy Rating	03-13	MT

Chart Ventyx Biosciences, Inc.

Duration

Period

More charts

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Companyâs pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.18 USD

Average target price

10.8 USD

Spread / Average Target

+395.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VENTYX BIOSCIENCES, INC.	-11.74%	154M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs